Table 1 Approved antibiotics from 2014 to 2021
From: Antimicrobial resistance crisis: could artificial intelligence be the solution?
Drug | Target pathogen | Class | Approval year | Approved by |
|---|---|---|---|---|
Dalbavancin | Gram-positive pathogens | Glycopeptide | 2014 | US FDA; EMA |
Tedizolid | Gram-positive pathogens | Oxazolidinone | 2014 | US FDA; EMA |
Oritavancin | Gram-positive pathogens | Glycopeptide | 2014 | US FDA |
Ceftolozane/tazobactam | β-lactamase enzyme producing bacteria | β-lactam/β-lactamase inhibitor | 2014 | US FDA; EMA |
Cefazidime/avibactam | CRE | β-lactam/β-lactamase inhibitor | 2015 | US FDA; EMA |
Isavuconazonium | Antifungal | Triazole | 2015 | US FDA |
Delafloxacin | Gram-positive pathogens | Fluoroquinolone | 2017 | US FDA; EMA |
Vaborbactam/meropenem | CRE | β-lactam/β-lactamase inhibitor | 2017 | US FDA; EMA |
Plazomicin | CRE | Aminoglycoside | 2018 | US FDA |
Eravacycline | CRE | Tetracycline | 2018 | US FDA; EMA |
Omadacycline | MRSA and CRE | Tetracycline | 2018 | USÂ FDA |
Relebactam + imipenem/Cilastatinilastatin | CRE, and potential activity for CRPA | β-lactam/β-lactamase inhibitor | 2019 | US FDA; EMA |
Lefamulin | MSSA | Pleuromutilin | 2019 | US FDA; EMA |
Pretomanid | XDR-TB | Nitroimidazole | 2019 | US FDA; EMA |
Lascufloxacin | Gram-positive pathogens | Fluoroquinolone | 2019 | PMDA |
Cefiderocol | CRAB, CRPA, CRE | Siderophore β-lactam (cephalosporin) | 2019 | US FDA; EMA |
Levonadifloxacin | Gram-positive pathogens | Fluoroquinolone | 2020 | CDSCO |
Contezolid | MRSA | Oxazolidinone | 2021 | US FDA; EMA; China |